Mantle Cell Lymphoma - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 354 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mantle Cell Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents
2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mantle Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Mantle Cell Lymphoma - Overview 10
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 11
Mantle Cell Lymphoma - Therapeutics under Development by Companies 12
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Mantle Cell Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Mantle Cell Lymphoma - Products under Development by Companies 20
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 24
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 25
AB Science SA 25
AbbVie Inc. 26
Acetylon Pharmaceuticals, Inc. 27
Actinium Pharmaceuticals, Inc. 28
Advancell 29
Affimed Therapeutics AG 30
Amgen Inc. 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
Bayer AG 34
Bristol-Myers Squibb Company 35
Celgene Corporation 36
Cellular Biomedicine Group, Inc. 37
Eisai Co., Ltd. 38
Eli Lilly and Company 39
EpiZyme, Inc. 40
Genentech, Inc. 41
Gilead Sciences, Inc. 42
GlaxoSmithKline Plc 43
Hutchison MediPharma Limited 44
ImmunoGen, Inc. 45
Immunomedics, Inc. 46
Incyte Corporation 47
Infinity Pharmaceuticals, Inc. 48
Johnson & Johnson 49
Karyopharm Therapeutics, Inc. 50
LFB S.A. 51
MedImmune, LLC 52
Merck & Co., Inc. 53
Millennium Pharmaceuticals, Inc. 54
MorphoSys AG 55
Nordic Nanovector ASA 56
Novartis AG 57
Onconova Therapeutics, Inc. 58
Onyx Pharmaceuticals, Inc. 59
Pfizer Inc. 60
Pharmacyclics, Inc. 61
Portola Pharmaceuticals, Inc. 62
Seattle Genetics, Inc. 63
Selvita SA 64
Sorrento Therapeutics, Inc. 65
Stemline Therapeutics, Inc. 66
TG Therapeutics, Inc. 67
Mantle Cell Lymphoma - Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Target 70
Assessment by Mechanism of Action 74
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
13197 - Drug Profile 82
AB-8779 - Drug Profile 84
abemaciclib - Drug Profile 85
abexinostat hydrochloride - Drug Profile 86
acadesine - Drug Profile 88
acalisib - Drug Profile 90
ACP-196 - Drug Profile 91
ACY-775 - Drug Profile 93
AFM-11 - Drug Profile 95
agatolimod sodium - Drug Profile 96
alisertib - Drug Profile 99
AMG-319 - Drug Profile 103
ASN-002 - Drug Profile 104
AT-7519 - Drug Profile 105
bendamustine hydrochloride - Drug Profile 108
Betalutin - Drug Profile 111
BLyS-gel - Drug Profile 113
BMS-986016 - Drug Profile 114
buparlisib hydrochloride - Drug Profile 115
carfilzomib - Drug Profile 119
CBM-C19.1 - Drug Profile 123
CBM-C20.1 - Drug Profile 124
CC-122 - Drug Profile 125
Cell Therapy for Oncology - Drug Profile 127
Cell Therapy to Target CD19 for Oncology - Drug Profile 128
Cell Therapy to Target ROR1 for Oncology - Drug Profile 129
cerdulatinib - Drug Profile 130
copanlisib hydrochloride - Drug Profile 131
daratumumab - Drug Profile 135
denintuzumab mafodotin - Drug Profile 138
duvelisib - Drug Profile 139
E-7449 - Drug Profile 141
entospletinib - Drug Profile 142
epratuzumab - Drug Profile 143
EPZ-015666 - Drug Profile 148
HMPL-523 - Drug Profile 149
ibrutinib - Drug Profile 150
ibrutinib + ublituximab + TGR-1202 - Drug Profile 157
idelalisib - Drug Profile 158
IGN-002 - Drug Profile 161
IMGN-529 - Drug Profile 162
IMMU-114 - Drug Profile 164
INA-01 - Drug Profile 165
INCB-39110 - Drug Profile 166
INCB-40093 - Drug Profile 168
inebilizumab - Drug Profile 169
ixazomib citrate - Drug Profile 171
JNJ-64052781 - Drug Profile 175
lenalidomide - Drug Profile 176
MEDI-0680 - Drug Profile 181
MEDI-551 + MEDI-0680 - Drug Profile 182
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 183
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 184
MOR-208 - Drug Profile 185
ON-123300 - Drug Profile 187
ONC-201 - Drug Profile 188
pevonedistat hydrochloride - Drug Profile 191
polatuzumab vedotin - Drug Profile 193
ribociclib - Drug Profile 195
SEL-120 - Drug Profile 198
selinexor - Drug Profile 200
SGN-CD70A - Drug Profile 206
SL-101 - Drug Profile 207
Small Molecule for Mantle Cell Lymphoma - Drug Profile 208
temsirolimus - Drug Profile 209
TGR-1202 - Drug Profile 211
tisagenlecleucel-T - Drug Profile 213
tretinoin - Drug Profile 216
ublituximab - Drug Profile 217
venetoclax - Drug Profile 219
vorinostat - Drug Profile 222
Mantle Cell Lymphoma - Recent Pipeline Updates 226
Mantle Cell Lymphoma - Dormant Projects 333
Mantle Cell Lymphoma - Discontinued Products 335
Mantle Cell Lymphoma - Product Development Milestones 336
Featured News & Press Releases 336
Appendix 348
Methodology 348
Coverage 348
Secondary Research 348
Primary Research 348
Expert Panel Validation 348
Contact Us 348
Disclaimer 349

List of Tables

Number of Products under Development for Mantle Cell Lymphoma, H2 2015 15
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 18
Number of Products under Development by Companies, H2 2015 (Contd..1) 19
Number of Products under Development by Companies, H2 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2015 21
Comparative Analysis by Late Stage Development, H2 2015 22
Comparative Analysis by Clinical Stage Development, H2 2015 23
Comparative Analysis by Early Stage Development, H2 2015 24
Products under Development by Companies, H2 2015 25
Products under Development by Companies, H2 2015 (Contd..1) 26
Products under Development by Companies, H2 2015 (Contd..2) 27
Products under Development by Companies, H2 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2015 29
Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2015 30
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H2 2015 31
Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 32
Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 33
Mantle Cell Lymphoma - Pipeline by Advancell, H2 2015 34
Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 35
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2015 36
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 37
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 38
Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2015 39
Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 40
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2015 41
Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 42
Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 43
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2015 44
Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 45
Mantle Cell Lymphoma - Pipeline by Genentech, Inc., H2 2015 46
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 47
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 48
Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 49
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 50
Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 51
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2015 52
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 53
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015 54
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 55
Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2015 56
Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015 57
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 58
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 59
Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2015 60
Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 61
Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2015 62
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2015 63
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 64
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H2 2015 65
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 66
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 67
Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 68
Mantle Cell Lymphoma - Pipeline by Selvita SA, H2 2015 69
Mantle Cell Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 70
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015 71
Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 72
Assessment by Monotherapy Products, H2 2015 73
Assessment by Combination Products, H2 2015 74
Number of Products by Stage and Target, H2 2015 76
Number of Products by Stage and Mechanism of Action, H2 2015 80
Number of Products by Stage and Route of Administration, H2 2015 84
Number of Products by Stage and Molecule Type, H2 2015 86
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 231
Mantle Cell Lymphoma - Dormant Projects, H2 2015 338
Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2015 339
Mantle Cell Lymphoma - Discontinued Products, H2 2015 340